Advertisement

Validation of 0–10 MS symptom scores in the Australian multiple sclerosis longitudinal study

Published:December 17, 2019DOI:https://doi.org/10.1016/j.msard.2019.101895

      Highlights

      • We developed a single-item 0–10 numeric rating scale: MSSymS.
      • The scale assessed 13 most common multiple sclerosis symptoms.
      • Walking/fatigue/pain/anxiety/depression/vision were validated here.
      • The scale had adequate concurrent validity and predictive validity.
      • The scale also had adequate temporal stability and responsiveness.

      Abstract

      Background

      Multiple sclerosis (MS) symptom measurements often use multiple-item scales per symptom, creating a high burden when multiple symptoms are assessed. We aimed to examine the validity, stability and responsiveness of single-item 0–10 numeric rating MS Symptom Scores (MSSymS).

      Methods

      The study included 1,985 participants from the Australian Multiple Sclerosis Longitudinal Study. Thirteen MS symptoms were assessed using the MSSymS, of which we were able to validate six (walking difficulties, fatigue, pain, feelings of anxiety, feelings of depression and vision problems). Comparison measures included Patient Determined Disease Steps (PDDS), Fatigue Severity Scale (FSS), Hospital Anxiety and Depression Scale (HADS), and Assessment of Quality of Life (AQoL). We used spearman rank correlation for concurrent validity, linear regression for predictive validity, intra-class correlations for stability, and percentage change for responsiveness.

      Results

      We found high correlations between walking difficulties and PDDS (r = 0.82), pain and AQoL-pain (r = 0.77), fatigue and FSS (r = 0.72); moderate correlations between feelings of anxiety and HADS-Anxiety (r = 0.68), feelings of depression and HADS-Depression (r = 0.63); and low correlation between vision and AQoL-vision (r = 0.43) For predictive validity, the graphs with quality of life were largely overlapping and the R2 of the regression lines were generally similar. The stability and responsiveness of the MSSymS were adequate.

      Conclusion

      The six assessed symptoms of the MSSymS performed equally well compared to validated comparison measures in terms of concurrent and predictive validity, temporal stability and responsiveness.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Balcer L
        • et al.
        Contrast letter acuity as a visual component for the multiple sclerosis functional composite.
        Neurology. 2003; 61: 1367-1373
        • Balcer L.J
        • et al.
        New low-contrast vision charts: reliability and test characteristics in patients with multiple sclerosis.
        Multiple Sclerosis J. 2000; 6: 163-171
        • Bjelland I.
        • Dahl A.A.
        • Haug T.T.
        • Neckelmann D.
        The validity of the hospital anxiety and depression scale: an updated literature review.
        J. Psychosom. Res. 2002; 52: 69-77
        • Campbell J.A
        • et al.
        A head-to-head comparison of the EQ-5D-5L and AQoL-8D multi-attribute utility instruments in patients who have previously undergone bariatric surgery.
        Patient-Patient-Centered Outcomes Res. 2016; 9: 311-322
        • Chen J
        • et al.
        Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.
        J. Neurol. Neurosurg. Psychiatry. 2018; 89: 1200-1207
        • de Vet H.C.
        • Terwee C.B.
        • Knol D.L.
        • Bouter L.M
        When to use agreement versus reliability measures.
        J. Clin. Epidemiol. 2006; 59: 1033-1039
        • Dworkin R.H
        • et al.
        Core outcome measures for chronic pain clinical trials: Immpact recommendations.
        Pain. 2005; 113: 9-19
        • Fox R.J
        • et al.
        Setting a research agenda for progressive multiple sclerosis: The international collaborative on progressive MS.
        Multiple Sclerosis J. 2012; 1352458512458169
        • Green R.
        • Kalina J.
        • Ford R.
        • Pandey K.
        • Kister I.
        SymptoMScreen: a tool for rapid assessment of symptom severity in MS across multiple domains.
        Appl. Neuropsychol. 2017; 24: 183-189
        • Gries K
        • et al.
        Literature review to assemble the evidence for response scales used in patient-reported outcome measures.
        J. Patient-Reported Outcomes. 2018; 2: 41
        • Herdman M
        • et al.
        Development and preliminary testing of the new five-level version of EQ-5d (EQ-5D-5L).
        Qual. Life Res. 2011; 20: 1727-1736
        • Hohol M.
        • Orav E.
        • Weiner H.
        Disease steps in multiple sclerosis a simple approach to evaluate disease progression.
        Neurology. 1995; 45: 251-255
        • Huber G.P.
        Temporal stability and response-order biases in participant descriptions of organizational decisions.
        Acad. Manage. J. 1985; 28: 943-950
        • Koch M.W.
        • Cutter G.
        • Stys P.K.
        • Yong V.W.
        • Metz L.M.
        Treatment trials in progressive MS—current challenges and future directions.
        Nature Rev. Neurol. 2013; 9: 496-503
        • Krupp L.B.
        • LaRocca N.G.
        • Muir-Nash J.
        • Steinberg A.D.
        The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus.
        Arch. Neurol. 1989; 46: 1121-1123
        • Learmonth Y.C.
        • Motl R.W.
        • Sandroff B.M.
        • Pula J.H.
        • Cadavid D.
        Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis.
        BMC Neurol. 2013; 13: 37
        • lriarte J.
        • Subirá M.L.
        • de Castro P.
        Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors.
        Multiple Sclerosis J. 2000; 6: 124-130
        • Marrie R.A.
        • Cutter G.
        • Tyry T.
        • Hadjimichael O.
        • Vollmer T.
        Validation of the narcoms registry: pain assessment.
        Multiple Sclerosis J. 2005; 11: 338-342
        • Mukaka M.M.
        A guide to appropriate use of correlation coefficient in medical research.
        Malawi Med. J. 2012; 24: 69-71
        • Nowinski C.J.
        • Miller D.M.
        • Cella D.
        Evolution of patient-reported outcomes and their role in multiple sclerosis clinical trials.
        Neurotherapeutics. 2017; 14: 934-944
        • O'connor A.B.
        • Schwid S.R.
        • Herrmann D.N.
        • Markman J.D.
        • Dworkin R.H.
        Pain associated with multiple sclerosis: systematic review and proposed classification.
        PAIN®. 2008; 137: 96-111
      1. Portney, L.G.Foundations of clinical research: applications to practice 3th (third) edition. (2009).

        • Portney L.G.
        • Watkins M.P.
        Foundations of clinical research: applications to practice. 892. Pearson/Prentice Hall, Upper Saddle River, NJ2009
        • Richardson J.
        • Iezzi A.
        • Khan M.A.
        • Maxwell A.
        Validity and reliability of the assessment of quality of life (AQoL)-8D multi-attribute utility instrument.
        Patient-Patient-Centered Outcomes Res. 2014; 7: 85-96
        • Safikhani S
        • et al.
        response scale selection in adult pain measures: Results from a literature review.
        J. Patient-Reported Outcomes. 2018; 2: 40
        • Schwartz C.E.
        • Vollmer T.
        • Lee H.
        Reliability and validity of two self-report measures of impairment and disability for MS.
        Neurology. 1999; 52 (63-63)
        • Shrout P.E.
        • Fleiss J.L
        Intraclass correlations: uses in assessing rater reliability.
        Psychol. Bull. 1979; 86: 420
        • Simmons R.D.
        • Tribe K.L.
        • McDonald E.A.
        Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management.
        J. Neurol. 2010; 257: 926-936
        • Spiegel B
        • et al.
        Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale.
        Aliment Pharmacol. Ther. 2009; 30: 1159-1170
        • Taylor B.V
        • et al.
        Assessing possible selection bias in a national voluntary MS longitudinal study in Australia.
        Multiple Sclerosis J. 2013; (1352458513481511)
        • Valko P.O.
        • Bassetti C.L.
        • Bloch K.E.
        • Held U.
        • Baumann C.R.
        Validation of the fatigue severity scale in a Swiss cohort.
        Sleep. 2008; 31: 1601-1607
        • Zigmond A.S.
        • Snaith R.P.
        The hospital anxiety and depression scale.
        Acta Psychiatr Scand. 1983; 67: 361-370